Zacks Investment Research Lowers Eisai (OTCMKTS:ESALY) to Hold

Zacks Investment Research downgraded shares of Eisai (OTCMKTS:ESALY) from a strong-buy rating to a hold rating in a research note released on Tuesday, reports.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

Separately, Citigroup upgraded Eisai from a sell rating to a neutral rating in a report on Monday, August 5th.

Shares of OTCMKTS:ESALY opened at $50.96 on Tuesday. Eisai has a 1 year low of $49.44 and a 1 year high of $101.80. The company has a market cap of $14.45 billion, a PE ratio of 24.85, a P/E/G ratio of 2.10 and a beta of 0.24. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.90 and a quick ratio of 1.66. The stock’s 50-day moving average is $52.54 and its 200 day moving average is $61.04.

Eisai Company Profile

Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia.

Read More: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit